The rise in obesity has led to increased metabolic diseases like insulin resistance, type 2 diabetes, and nonalcoholic fatty liver disease (NAFLD), the most common chronic liver disease...
Miu Lai (Milly) Ng,
FNP-BC, MPH (Harvard)
Nurse Practitioner, Tufts Medical Center
MASLD: A Growing Global Health Concern Driven by Obesity, Diabetes, and Cardiovascular Risks
The terms nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) have been replaced by metabolic-dysfunction-associated steatotic liver disease (MASLD)...
Rezdiffra and Noncirrhotic Non-alcoholic Steatohepatitis
The first US Food and Drug Administration-approved medication to treat noncirrhotic non-alcoholic steatohepatitis, otherwise known as NASH, is Rezdiffra (resmetirom)....
